Eric Vivier

Has grant

Chief Science Officer

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Eric Vivier is the Chief Science Officer at Innate Pharma in France. His research areas include the biology and therapeutic applications of natural killer (NK) cells, with a specific focus on cancer therapies and immune response mechanisms. Recent publications highlight his contributions to understanding the role of innate lymphoid cells and the metabolic dysfunction of immune cells in cancer settings. Through his work, he aims to harness the potential of NK cells and develop innovative treatments for various malignancies.

Recent Grants

Grant: Close

Regulation of lung immune-epithelial networks sensing environmental change

Open Date: 2023-07-01

Close Date: 2026-06-30

Grant: Close

Generation of therapeutic antibodies targeting type 2 Innate Lymphoid cells in asthma

Open Date: 2020-01-01

Close Date: 2021-12-31

Grant: Close

Targeting Innate Lymphoid Cells

Open Date: 2017-01-01

Close Date: 2021-12-31

Grant: Close

TILC

Open Date: 2017-01-01

Close Date: 2021-12-01

Grant: Close

Identification of CIS as a potent checkpoint in NK cell-mediated tumour immunity

Open Date: 2017-01-01

Close Date: 2020-12-31

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (7)

Roberta Castriconi

Associate Professor

University of Genoa

ITALY

View details

Yasuharu Nagahama, Ph.D.

Laboratory Head

JAPAN

View details

James Wing

Associate Professor

JAPAN

View details

Ari Waisman

Institue Director and full Professor

University Medical Center of the Johannes Gutenberg University Mainz

GERMANY

View details

Frank Cichocki

University of Minnesota

UNITED STATES

View details

Emilie Narni-Mancinelli

Inserm u1183

FRANCE

View details

Michael E. O'Dwyer

National University of Ireland Galway

IRELAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Eric Vivier

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

Innate lymphoid cells originate from fetal liver–derived tissue-resident progenitors

Harnessing NK cells in cancer therapies

Innate lymphoid cell (ILC) 1- and NK cell-derived, early IFNγ release depends on ICER and promotes protection against Leishmania major infection.

Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer

Genome-wide CRISPR/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing

Genome-wide CRISPR/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing.

CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation

High-dimensional single-cell analysis of human natural killer cell heterogeneity

Natural killer cell therapies.

New immune cell engagers for cancer immunotherapy.

On blood and tissue-resident natural killer cells.

Natural killer cells and engagers: Powerful weapons against cancer.

RIPK3 and caspase-8 interpret cytokine signals to regulate ILC3 survival in the gut.

Author Correction: Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cell.

Deletion of the mRNA endonuclease Regnase-1 promotes NK cell anti-tumor activity via OCT2-dependent transcription of Ifng.

Vaccins thérapeutiques anti-tumoraux

A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma.

Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities.

Germinal center-dependent and -independent immune responses of tumor-infiltrating B cells in human cancers

Collaborators (7)

Roberta Castriconi

Yasuharu Nagahama, Ph.D.

James Wing

Ari Waisman

Frank Cichocki

Emilie Narni-Mancinelli

Michael E. O'Dwyer

Make your next move.